Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
GynCAT is a prospective cohort study that will be conducted on female patients with gynecologic malignancies scheduled for systemic antineoplastic treatment, aiming at development and validation of a Risk Assessment Model (RAM) for Venous Thromboembolism (VTE) in this specific population.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Female sex;
• Diagnosis of gynecologic neoplasm (ovarian, tubal, uterine, cervical, vaginal, vulvar neoplasm);
• Planned new line of systemic antineoplastic treatment;
• Age of 18 years or older;
• Accordance of Informed Consent.
Locations
Other Locations
Italy
Agostino Gemelli University Polyclinic Foundation IRCCS
RECRUITING
Rome
Contact Information
Primary
Roberto Pola, PhD; MD
roberto.pola@policlinicogemelli.it
+39 0630157075
Backup
Paolo Santini, MD
paolo.santini@guest.policlinicogemelli.it
Time Frame
Start Date: 2024-04-15
Estimated Completion Date: 2026-09-30
Participants
Target number of participants: 1800
Treatments
Patients affected by Gynecologic Cancer undergoing systemic antineoplastic treatment
Study population will consist of subsequent patients prospectively enrolled at the time of prescription of a new line of systemic antineoplastic treatment for a gynecologic oncological disease, defined as ovarian, tubal, uterine, cervical, vaginal, or vulvar neoplasm
Related Therapeutic Areas
Sponsors
Leads: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborators: Fondazione Umberto Veronesi